La nicchia ipossica come target terapeu1co nel microambiente del mieloma mul1plo
|
|
- Shana Green
- 8 years ago
- Views:
Transcription
1 La nicchia ipossica come target terapeu1co nel microambiente del mieloma mul1plo Nicola Giuliani, PhD, MD Hematology, University of Parma
2 OSTEOBLAST NICHE: ROLE OF HYPOXIA
3 BONE MARROW (BM) MICROENVIRONMENT AND MULTIPLE MYELOMA (MM) CELLS Osteoblast Bone forma)on inhibi)on Osteoclast Bone resorp)on MM cell Stromal cells Cytokine produc)on Lymphocyte Immunosuppression Endothelial cell Angiogenesis
4 PATHOPHYSIOLOGY OF OSTEOBLAST SUPPRESSION IN MM MM cell IL- 7, IL- 3 MM cell Mesenchymal/ stromal cell VCAM- 1 VLA- 4 VLA- 4 VCAM- 1 COL I - ALP - OC - OPN - T cell Runx2/Cbfa1 IL- 3 DKK- 1, SFRP2, SFRP3 WNT? Immature Osteoblast COL I ++ ALP ++ OPN + OC + Mature Osteoblast Ehrlich LA-Giuliani N, Blood, 2005 Giuliani N et al Blood, 2006 Giuliani N et al Blood, 2005 Tian E et al. NEJM, 2003 Giuliani N et al. Cancer Res, 2007
5 MECHANISMS INVOLVED IN MULTIPLE MYELOMA ANGIOGENIC SWITCH IGF-1 IL-6 VEGF IL-6 OPN OPN HOXB7 ING4 MM cell VEGF IL-8 TGFβ HGF bfgf p0 2? ANG-1 OPN Stromal cells Giuliani N et al Blood 2003 Colla S et al. Leukemia 2005 Colla S et al Blood 2007 Storti P et al Leukemia 2011 VEGF bfgf TGFβ OPN TIE2 ANGIOGENESIS Blood vessel
6 HYPOXIA- INDUCIBLE FACTOR (HIF)- 1α: A KEY TRANSCRIPTION FACTOR NORMOXIA Angiogenesis HYPOXIA
7 PREVIOUSLY REPORTED The bone marrow microenvironment is hypoxic in MM pa)ents. 1 HIF- 1α is overexpressed by MM cells in the bone marrow. 1 Under normoxic condi)on, some HMCLs (JJN3, U266) and the 28% of CD138+ cells from MM pa)ents express HIF- 1α showing an oxygen- independent regula)on. 1, 2 Hif- 1α protein level and ac)vity in MM cells under normoxic HIF- 1α condi)ons modulates is regulated the pro- angiogene)c by oncogenic profile c- Myc of to MM influence cells. 1 VEGF secre)on and angiogenic ac)vity. Hypoxia and HIF- 1α expression leads to the forma)on of giant osteoclasts during mouse embryogenesis 3 and enhance osteoly)c bone metastases of breast cancer Colla S et al. Leukemia Zhang J et al. Cancer Res Bozec A et al. Nature Hiraga T et al. Cancer Res 2007
8
9 AIM OF STUDY Inves)gate the effect of a stable HIF- 1α inhibi)on in MM cells on cell prolifera)on, survival and on MM- induced angiogenesis and osteolysis either in vitro and in vivo.
10 LENTIVIRAL STABLE INHIBITION OF HIF- 1α JJN3/RPMI MISSION shrna anti HIF-1α Sigma-Aldrich RPMI +10% FBS + puromycin 4 ug/ml for 15 days
11 SPECIFICITY OF VECTORS ANTI- HIF1- α
12 EFFECT OF HIF1- α SUPPRESSION ON HMCLs PROLIFERATION AND SURVIVAL JJN3 RPMI JJN3 RPMI
13 DOWN- REGULATION OF PRO- ANGIOGENIC MOLECULES OF JJN3 BY HIF- 1α SUPPRESSION Modulated Genes Microarray data JJN3- an)- HIF- 1α vs JJN3- plko NORMOXIA COMMON HYPOXIA Pro- angiogenic genes down- regula)on VEGF IL8 CCL2 MMP9
14 DOWN- REGULATION OF PRO- ANGIOGENIC MOLECULES OF JJN3 BY HIF- 1α SUPPRESSION
15 EFFECT OF HIF- 1α INIBITION ON PRO- OSTEOCLASTOGENIC CYTOKINES PRODUCTION IN HMCLs
16 1. TUMOR GROWTH IN IN VIVO MODEL 1. Subcutaneous injec)on in NOD- SCID mice with JJN3 wt, JJN3- plko, JJN3- an)- HIF- 1α of three groups of 6 animals. 2. A`er 20 days the mice were sacrificed.
17 IMMUNOHISTOCHEMISTRY
18 2. TUMOR GROWTH IN IN VIVO MODEL 1. Intra- )bial injec)on in SCID and NIH- III nude mice with saline solu)on, JJN3- plko, JJN3- an) HIF- 1α. 2. A`er 3-4 weeks the mice were sacrificed.
19 HIF- 1α SUPPRESSION BLUNTS ANGIOGENESIS IN THE IN VIVO MODEL
20 HIF- 1α SUPPRESSION INHIBITS BONE DESTRUCTION IN THE IN VIVO MODEL
21 SUMMARY We show that: A selec)ve and stable HIF- 1α inhibi)on did not directly induce a significant effect on MM cell prolifera)on and survival in vitro. HIF- 1α suppression modified the pro- angiogenic and osteoclastogenic profiles of MM cells either under normoxic or hypoxic condi)ons.
22 SUMMARY A strong effect on tumor growth in both models (subcutaneous and intra- )bial) by HIF- 1α suppression mainly due to the inhibi)on of angiogenesis. In the intra- )bial bone model, HIF- 1α suppression affects MM- induced in vivo forma)on of osteoly)c bone lesions. These results suggest that HIF- 1α is a poten)al therapeu)c target in MM microenvironment.
23 HIF- 1α AND DRUGS v The sulfonanilides ELR510490, ELR510444, ELR and ELR completely inhibit prolifera)on of all tested MM cell lines at nm concentra)ons. The compounds show a pronounced effect on the HIF1A signaling pathway. v EZN- 2968: a RNA antagonist that specifically binds and inhibits the expression of HIF- 1A mrna. Ongoing phase I studies in adults with advanced solid tumors.
24 MM MICROENVIRONMENT AND NEW DRUGS IN MM THERAPY CYTOTOXICITY ThaI / Len. CTL NK cells IL-2 IFNγ GROWN INHIBITION AND APOPTOSIS PBMC CITOKINES INHIBITION ThaI / Len. Bortezomib Len. Bortezomib MM CELLS ADHESION INHIBITION ThaI / Len. Bortezomib IL-6 IGF-1 VEGF SDF-1α IL-1β VEGF bfgf ThaI / Len., Bortezomib Blood Vessels STROMAL cells ANTI-ANGIOGENIC
25 HIF- 1α AND THE NEW ANTI- MM DRUGS v BORTEZOMIB Repressed HIF- 1a ac)vity by inhibi)ng the recruitment of p300 coac)vator à VEGF down- regula)on. v LENALIDOMIDE Shin Dh et al. Blood 2008 An)oxidants protect MM cells from bortezomib- mediated cell death. GCLM and HMOX1 are upregulated a`er treatment with Bortezomib. Tight links between sensi)vity to proteasome inhibi)on and redox homeostasis in MM cells. Nerini-Molteni S et al. Br J Haematol 2008 Strong inhibitory effect on hypoxia- induced endothelial cell forma)on of cords and HIF- 1α expression. Lu L et al. Microvasc Res 2009
26 EFFECT OF HIF1- α INHIBITION AND DRUGS ON HMCLs PROLIFERATION AND SURVIVAL
27 ONGOING STUDY In vivo mouse model in NOD- SCID mice Subcutaneous injec)on with JJN3wt, JJN3 plko and JJN3 an)- HIF1α Mice treatment with Lenalidomide and other IMIDs Synergis)c/addi)ve effects on tumors development?
28 EMATOLOGIA E CTMO, PARMA (Dir. Franco Aversa) LABORATORY STAFF Paola Stor) Marina Bolzoni Denise Toscani Daniela Guasco CLINICAL STAFF Benedeia Dalla Palma Dipar)mento di Salute Animale, PARMA Gaetano Donofrio U.O. di Anatomia Patologica, PARMA Eugenia Martella Cris)na Mancini THANKS TO Ematologia, IRCCS POLICLINICO, MILANO Luca Agnelli Ka)a Todoer) Antonino Neri MD Anderson Cancer Center, TX, USA Simona Colla Hematology, University of Indiana, USA G. Dave Roodman Laboratorio AIRC, Oncologia, G. Gaslini, Genova Irma Airoldi
CONTRACTING ORGANIZATION: University of Alabama at Birmingham Birmingham, AL 35294
AD Award Number: W81XWH-08-1-0030 TITLE: Regulation of Prostate Cancer Bone Metastasis by DKK1 PRINCIPAL INVESTIGATOR: Gregory A. Clines, M.D., Ph.D. CONTRACTING ORGANIZATION: University of Alabama at
More informationMULTIPLE MYELOMA. Dr Malkit S Riyat. MBChB, FRCPath(UK) Consultant Haematologist
MULTIPLE MYELOMA Dr Malkit S Riyat MBChB, FRCPath(UK) Consultant Haematologist Multiple myeloma is an incurable malignancy that arises from postgerminal centre, somatically hypermutated B cells.
More informationMonoclonal Antibodies in The Treatment of Multiple Myeloma
Monoclonal Antibodies in The Treatment of Multiple Myeloma Sundar Jagannath, MD Professor of Medicine Mt. Sinai School of Medicine New York, NY The Tisch Cancer Institute Disclosure 2 Honorarium: Celgene
More information12. November 2013 Jan Endell. From library to bedside: Potential of the anti-cd38 antibody MOR202 in combination therapy of multiple myeloma
12. November 2013 Jan Endell From library to bedside: Potential of the anti-cd38 antibody MOR202 in combination therapy of multiple myeloma The MorphoSys Pipeline 21 Clinical Programs, 82 Total Program
More informationPROSPETTIVE FUTURE NEL TRATTAMENTO. Cinzia Ortega Dipartimento di Oncologia Medica Fondazione del Piemonte per l Oncologia I.R.C.C.S.
PROSPETTIVE FUTURE NEL TRATTAMENTO MEDICO DEL mrcc Cinzia Ortega Dipartimento di Oncologia Medica Fondazione del Piemonte per l Oncologia I.R.C.C.S. Candiolo Future strategies in mrcc Improve therapeutic
More informationPulling the Plug on Cancer Cell Communication. Stephen M. Ansell, MD, PhD Mayo Clinic
Pulling the Plug on Cancer Cell Communication Stephen M. Ansell, MD, PhD Mayo Clinic Why do Waldenstrom s cells need to communicate? Waldenstrom s cells need activating signals to stay alive. WM cells
More informationThe Effect of Myeloma Cells on Bone Metabolism is Heterogenous and Correlates with Underlying Genetic Lesions and Bone Disease In Vivo
The Effect of Myeloma Cells on Bone Metabolism is Heterogenous and Correlates with Underlying Genetic Lesions and Bone Disease In Vivo Deepika Kassen 1, Neil Rabin 1, Darren Lath 2, Peter Croucher 2 and
More informationEvaluation of focal adhesions as new therapeutic targets in acute myeloid leukemia
Evaluation of focal adhesions as new therapeutic targets in acute myeloid leukemia Dr Jordi Sierra Gil IRHSP Institut de Recerca Hospital de la Santa Creu i Sant Pau Dr. Miguel Ángel Sanz Alonso Fundación
More informationB Cell Generation, Activation & Differentiation. B cell maturation
B Cell Generation, Activation & Differentiation Naïve B cells- have not encountered Ag. Have IgM and IgD on cell surface : have same binding VDJ regions but different constant region leaves bone marrow
More informationA disease and antibody biology approach to antibody drug discovery
A disease and antibody biology approach to antibody drug discovery Björn Frendéus, PhD VP, Preclinical research Presenter: Björn Frendéus Date: 2011-11-08 1 Antibodies have revolutionized Cancer Treatment!
More informationa Phase 2 prostate cancer clinical trial is ongoing. Table 2: Squalamine vs Standard-of-care literature
PRODUCT FACT SHEET Spring 2007 MISSION STATEMENT Genaera Corporation is a biopharmaceutical company with a focus on metabolic and respiratory diseases. The compounds in the Genaera pipeline address signal
More informationDepartment of BioScience Technology Chung Yuan Christian University 2015/08/13
Department of BioScience Technology Chung Yuan Christian University 2015/08/13 Cancer Cells Cancer, the 1st leading cause of death, is an example of a disease that arises from abnormalities in cell function
More informationSuccesses and Limitations of Targeted Therapies in Renal Cell Carcinoma
g Tumor Res. Basel, Karger, 2014, vol 41, pp 98 112 (DOI: 10.1159/000355906) Successes and Limitations of Targeted Therapies in Renal Cell Carcinoma Marc Pracht Dominik Berthold Medical Oncology Unit,
More informationHow To Expand Hematopoietic Stem Cells
Purification and Expansion of Hematopoietic Stem Cells Based on Proteins Expressed by a Novel Stromal Cell Population Our bodies are constantly killing old, nonfunctional, and unneeded cells and making
More informationInflammatory Cytokine-induced Expression of Vasohibin-1 by Rheumatoid Synovial Fibroblasts
9 6 6 958 Inflammatory Cytokine-induced Expression of Vasohibin- by Rheumatoid Synovial Fibroblasts a b c a a a a d e a* a a b c d e 5 6 6 9 5 56 67 7 ʼ ʼ ʼ ʼ ʼ ʼ ʼ ʼ 5 6 6 ʼ 5 75 989 6 69 8 95 56 56896
More informationHow To Understand The Effects Of A Drug On Your Health
Farmacologia degli inibitori TK e mtor Romano Danesi Professore ordinario di Farmacologia UOC Farmacologia Universitaria Azienda Ospedaliero-Universitaria Pisana Dipartimento di Medicina Interna Università
More informationLEUKEMIA LYMPHOMA MYELOMA Advances in Clinical Trials
LEUKEMIA LYMPHOMA MYELOMA Advances in Clinical Trials OUR FOCUS ABOUT emerging treatments Presentation for: Judith E. Karp, MD Advancements for Acute Myelogenous Leukemia Supported by an unrestricted educational
More informationImmune Checkpoint Blockade in Acute Myeloid Leukemia. Kinsey McCormick Hematology Fellow s Conference January 10, 2014
Immune Checkpoint Blockade in Acute Myeloid Leukemia Kinsey McCormick Hematology Fellow s Conference January 10, 2014 Overview Overview of immune checkpoints Immune checkpoints as mechanism of immune evasion
More informationMultiple myeloma and bone disease: pathogenesis and current therapeutic approaches
HIPPOKRATIA 76 2010, 14, 2: 76-81 PASCHOS KA REVIEW ARTICLE Multiple myeloma and bone disease: pathogenesis and current therapeutic approaches Papadopoulou EC, Batzios S P, Dimitriadou M, Perifanis V,
More informationPathophysiology of bone metastasis : how does it apply to pain treatment in palliative care? JP Vuillez, Grenoble, France
Pathophysiology of bone metastasis : how does it apply to pain treatment in palliative care? JP Vuillez, Grenoble, France Bone metastases 70 % of prostate and breast cancers 30 % of lung, bladder and thyroid
More informationINSERM/ A. Bernheim. Overcoming clinical relapse in multiple myeloma by understanding and targeting the molecular causes of drug resistance
A. Bernheim Overcoming clinical relapse in multiple myeloma by understanding and targeting the molecular causes of drug resistance OVER-MyR is funded by the European Commission within its FP7 specific
More informationBasic Science in Medicine
Medical Journal of th e Islamic Republic of Iran Volume 18 Number 3 Fall 1383 November 2004 Basic Science in Medicine ] EXPANSION OF HUMAN CORD BLOOD PRIMITIVE PROGENITORS IN SERUM-FREE MEDIA USING HUMAN
More informationPersonalized, Targeted Treatment Options Offer Hope of Multiple Myeloma as a Chronic Disease
/publications/targeted-therapy-news/2012/november-2012/personalized-targeted-treatment-options- Offer-Hope-of-Multiple-Myeloma-as-a-Chronic-Disease Personalized, Targeted Treatment Options Offer Hope of
More informationNICOLA GIULIANI MD, PhD (Pisa 11/11/1968) Work address: PRESENT POSITIONS Titles and Positions Participation in committees Awards and Grants
NICOLA GIULIANI MD, PhD (Pisa 11/11/1968) Nationality and citizenship:italian Resident: Via Bixio 60, 43100 Parma, Italy Work address: Universitaria di Parma Via Gramsci 14, 43126, Parma, Italy, Phone:
More informationHow To Treat Mesothelioma With A Tumor Stem Cell Inhibitor
FAK INHIBITOR DEFACTINIB (VS-6063) TARGETS MESOTHELIOMA CANCER STEM CELLS Rationale for maintenance therapy after conventional therapy Jonathan Pachter, Ph.D. Vice President of Research, Verastem, Inc.
More informationH. Richard Alexander, Jr., M.D. Department of Surgery and The Greenebaum Cancer Center University of Maryland School of Medicine Baltimore, Md
Major Advances in Cancer Prevention, Diagnosis and Treatment~ Why Mesothelioma Leads the Way H. Richard Alexander, Jr., M.D. Department of Surgery and The Greenebaum Cancer Center University of Maryland
More informationTargeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma
The Use of Kinase Inhibitors: Translational Lab Results Targeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma Sheelu Varghese, Ph.D. H. Richard Alexander, M.D.
More informationSupplemental Information. McBrayer et al. Supplemental Data
1 Supplemental Information McBrayer et al. Supplemental Data 2 Figure S1. Glucose consumption rates of MM cell lines exceed that of normal PBMC. (A) Normal PBMC isolated from three healthy donors were
More informationWhat is Cancer? Cancer is a genetic disease: Cancer typically involves a change in gene expression/function:
Cancer is a genetic disease: Inherited cancer Sporadic cancer What is Cancer? Cancer typically involves a change in gene expression/function: Qualitative change Quantitative change Any cancer causing genetic
More informationChemotherapy resistance in acute myeloid leukemia: the role of adhesion
Chemotherapy resistance in acute myeloid leukemia: the role of adhesion Joe C. Huang, M.D. Research Elective 8/09-10/09 Mentor: Pamela S. Becker, M.D., Ph.D. Associate Professor of Medicine/Hematology
More informationCancer SBL101. James Gomes School of Biological Sciences Indian Institute of Technology Delhi
Cancer SBL101 James Gomes School of Biological Sciences Indian Institute of Technology Delhi All Figures in this Lecture are taken from 1. Molecular biology of the cell / Bruce Alberts et al., 5th ed.
More informationGriffith University - Case for Support. Mesothelioma Research Program
Griffith University - Case for Support Mesothelioma Research Program Professor Lyn Griffiths Director, Dean, Research and Director, Genomics Research Centre (GHI) Established in 2007. Integrated health
More informationUpdate in Hematology Oncology Targeted Therapies. Mark Holguin
Update in Hematology Oncology Targeted Therapies Mark Holguin 25 years ago Why I chose oncology People How to help people with possibly the most difficult thing they may have to deal with Science Turning
More informationThe Therapeutic Potential of Human Umbilical Cord Blood Transplantation for Neonatal Hypoxic-Ischemic Brain Injury and Ischemic Stroke
The Therapeutic Potential of Human Umbilical Cord Blood Transplantation for Neonatal Hypoxic-Ischemic Brain Injury and Ischemic Stroke a,b* b,c a a b b b b a b a b c 430 Wang et al. Acta Med. Okayama Vol.
More informationA disease of populations of cells that live, divide, invade and spread without regard to normal limits
1 Targeted Cancer Therapies Mark McKeage Medical Oncology Specialist Professor in Clinical Pharmacology 2 Cancer Definition- A disease of populations of cells that live, divide, invade and spread without
More informationB Cells and Antibodies
B Cells and Antibodies Andrew Lichtman, MD PhD Brigham and Women's Hospital Harvard Medical School Lecture outline Functions of antibodies B cell activation; the role of helper T cells in antibody production
More informationDrug Development Services
Drug Development Services USING BLOOD AND BONE MARROW PRIMARY CELL SYSTEMS Clinically Relevant In Vitro Assays Broad Spectrum of Drug Classes Multi-Species Platforms Enhancing Drug Development through
More informationOPG-Fc inhibits ovariectomy-induced growth of disseminated breast cancer cells in bone.
Title of the poster Authors Sheffield Cancer Research Centre University of Sheffield OPG-Fc inhibits ovariectomy-induced growth of disseminated breast cancer cells in bone. Dr Penelope Ottewell Background
More informationUnderstanding the Immune System in Myeloma
Brian GM Durie Understanding the Immune System in Myeloma Living Well with Myeloma Teleconference Series Thursday, March 19 th 2015 1 The Immune System is Like a Swiss Watch B Cell T Cell Plasma Cell Changing
More informationCombining Immunotherapy and Targeted Therapy in Melanoma
Combining Immunotherapy and Targeted Therapy in Melanoma 8:45 am - 9:15 am Antoni Ribas, M.D., h.d. rofessor of Medicine rofessor of Surgery rofessor of Molecular and Medical harmacology Director, Tumor
More informationEffectively Exploiting Big Data with Semantics
Effectively Exploiting Big Data with Semantics Thomas C. Rindflesch, Ph.D. National Library of Medicine, National Institutes of Health Digital Government Institute s Government Big Data Conference, October
More informationNuovi orientamenti nel cord blood banking
Nuovi orientamenti nel cord blood banking Laura Salvaneschi Banca del Sangue del Cordone Ombelicale Università degli Studi di Pavia IRCCS Policlinico San Matteo Pavia New directions in Cord Blood Banking
More information11.30 13.30. The writing tests, interviews, training opportunities and career development What to expect of life in a MedComms agency
The writing tests, interviews, training opportunities and career development What to expect of life in a MedComms agency Presenting yourself to the agencies Recognising your existing skills & strengths
More informationStem cells possess 2 main characteristics: Sources of pluripotent stem cells: -Long-term self renewal. -The inner cell mass of the blastocyst.
Stem cells possess 2 main characteristics: -Long-term self renewal. - They give rise to all types of differentiate cells. Sources of pluripotent stem cells: -The inner cell mass of the blastocyst. - Fetal
More informationLes liasons dangerouses: infiammazione e cancro
Dipartimento di Diagnostica per Immagini e Medicina di Laboratorio Department of Morphology, Surgery and Experimental Medicine Center of Excellence MIUR for the Study of Inflammation (ICSI) Ferrara University
More informationTECHNICAL INSIGHTS TECHNOLOGY ALERT
TECHNICAL INSIGHTS TECHNOLOGY ALERT UNLOCKING BREAST CANCER TUMORS' DRUG RESISTANCE A troubling phenomenon in breast cancer treatment is that some patients tumors become resistant to treatments over time.
More informationClinical Trials for Patients with
Clinical Trials for Patients with Malignant Pleural Mesothelioma Lee M. Krug, M.D. Memorial Sloan-Kettering Cancer Center New York, New York Challenges in MPM Clinical Trials Mesothelioma is a rare disease,
More informationOverview. Transcriptional cascades. Amazing aspects of lineage plasticity. Conventional (B2) B cell development
Overview B cell development Transcriptional cascades Amazing aspects of lineage plasticity Conventional (B2) B cell development What happens to an autoreactive B cell? B1 vs B2 cells Key anatomical sites
More informationFuture strategies for myeloma: An overview of novel treatments In development
Future strategies for myeloma: An overview of novel treatments In development Dr. Matthew Streetly Guys and St. Thomas NHS Trust How far have we come? Melphalan and prednisolone VAD Autologous SCT Thalidomide
More informationSTEM CELL FELLOWSHIP
Module I: The Basic Principles of Stem Cells 1. Basics of Stem Cells a. Understanding the development of embryonic stem cells i. Embryonic stem cells ii. Embryonic germ cells iii. Differentiated stem cell
More informationTITLE: Treatment of Prostate Cancer with a DBP-MAF-Vitamin D Complex to Target Angiogenesis and Tumorigenesis
AD AWARD NUMBER: W81XWH-04-1-0010 TITLE: Treatment of Prostate Cancer with a DBP-MAF-Vitamin D Complex to Target Angiogenesis and Tumorigenesis PRINCIPAL INVESTIGATOR: Michael W. Fannon, Ph.D. CONTRACTING
More informationGENETIC PROFILES AND TARGETED TREATMENT OF CANCER - PERSONALIZED MEDICINE
GENETIC PROFILES AND TARGETED TREATMENT OF CANCER - PERSONALIZED MEDICINE Branko Zakotnik MD, PhD Department of Medical Oncology Institute of Oncology Ljubljana 1 I have no conflict of interest to declare
More informationCD22 Antigen Is Broadly Expressed on Lung Cancer Cells and Is a Target for Antibody-Based Therapy
CD22 Antigen Is Broadly Expressed on Lung Cancer Cells and Is a Target for Antibody-Based Therapy Joseph M. Tuscano, Jason Kato, David Pearson, Chengyi Xiong, Laura Newell, Yunpeng Ma, David R. Gandara,
More informationEffets biologiques des facteurs de croissance sur la régénération musculaire
Effets biologiques des facteurs de croissance sur la régénération musculaire Xavier Bigard (MD, PhD) Professeur Agrégé du Val-de-Grâce Institut de Recherche Biomédicale des Armées (IRBA) La Tronche (Grenoble)
More informationCancer and the immune system: can we beat cancer at its own game?
Cancer and the immune system: can we beat cancer at its own game? Andrew R. Haas, MD, PhD Assistant Professor of Medicine University of Pennsylvania Medical Center Philadelphia, Pa Why can t immune
More informationImmunotherapy for Multiple Myeloma. Sarah Holstein, MD, PhD April 2, 2015 MIR-508
Immunotherapy for Multiple Myeloma Sarah Holstein, MD, PhD April 2, 2015 MIR-508 Outline Myeloma overview IMiDs Monoclonal antibodies Anti-CS1 Vaccines Dendritic cell/myeloma fusion Multiple Myeloma Monoclonal
More informationDevelopments in Biomarker Identification and Validation for Lung Cancer
Developments in Biomarker Identification and Validation for Lung Cancer Alexandre Passioukov, MD, PhD Alexandre.Passioukov@eortc.be Contents Introduction Lung cancer pathogenesis NSCLC treatment options
More informationThe recruitment of exogenous endothelial progenitor cells in lung tumor model of nude mice
窑 Original Article 窑 Chinese Journal of Cancer The recruitment of exogenous endothelial progenitor cells in lung tumor model of nude mice Qiang Peng 1, Ming Liu 1, Shu Min Song 1, Xian Hua Li 2, Yi Hua
More informationGene Therapy. The use of DNA as a drug. Edited by Gavin Brooks. BPharm, PhD, MRPharmS (PP) Pharmaceutical Press
Gene Therapy The use of DNA as a drug Edited by Gavin Brooks BPharm, PhD, MRPharmS (PP) Pharmaceutical Press Contents Preface xiii Acknowledgements xv About the editor xvi Contributors xvii An introduction
More informationMultiple Myeloma (Event Driven)
Brochure More information from http://www.researchandmarkets.com/reports/2234830/ Multiple Myeloma (Event Driven) Description: The 2010 multiple myeloma (myeloma) market garnered impressive sales despite
More informationBone Disease in Myeloma. St. Petersburg, Russia September 16, 2009
Bone Disease in Myeloma St. Petersburg, Russia September 16, 2009 Bi Brian G.M. GMDurie, M.D. MD Bone Disease in Myeloma Lytic Lesions Spike Bone Marrow Plasma Cells Collapse of Vertebrae Biology of Myeloma
More informationThe immune system. Bone marrow. Thymus. Spleen. Bone marrow. NK cell. B-cell. T-cell. Basophil Neutrophil. Eosinophil. Myeloid progenitor
The immune system Basophil Neutrophil Bone marrow Eosinophil Myeloid progenitor Dendritic cell Pluripotent Stem cell Lymphoid progenitor Platelets Bone marrow Thymus NK cell T-cell B-cell Spleen Cancer
More informationMULTIPLE MYELOMA is an incurable hematologic
Gallium Nitrate in Multiple Myeloma: Prolonged Survival in a Cohort of Patients With Advanced-Stage Disease Ruben Niesvizky Multiple myeloma is characterized by bone destruction mediated by osteoclastic
More informationDisclosure. Gene Therapy. Transfer of genes into cells Expression of transferred genes
Disclosure Equity interest in Genetix Pharm. Inc. Exclusive license of retroviral cell lines from Columbia No direct participation in MDR clinical trials Columbia U. annual reporting FDA Gene Therapy Transfer
More informationChapter 8. Summary, general discussion and future perspectives
Summary, general discussion and future perspectives 115 Summary Multiple Myeloma (MM) is characterized by a malignant proliferation of monoclonal plasma cells in the bone marrow, clinical presenting by
More informationTypes of Cancers [-oma growth ]!
Cancer: disease of transcription factors and replication 1 Uncontrolled cell growth and division -> immortalized cells -> tumor growth -> metastasis (cells float away from tumor and spread throughout the
More informationAnti-CD38 anti-cd3 bispecific antibody in multiple myeloma
Anti-CD38 anti-cd3 bispecific antibody in multiple myeloma David E. Szymkowski Senior Director, Biotherapeutics Proteins by Design 1960s...1980s...2000s... Where are the bispecific antibody drugs? J Exp.
More informationFastTest. You ve read the book... ... now test yourself
FastTest You ve read the book...... now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. Please refer back to relevant sections
More informationMonoclonal Antibodies in Cancer. Ralph Schwall, PhD Associate Director, Translational Oncology Genentech, Inc.
Monoclonal Antibodies in Cancer Ralph Schwall, PhD Associate Director, Translational Oncology Genentech, Inc. Disclaimer I had nothing to do with Herceptin Using lessons learned in new antibody projects
More informationMetastasis. brain metastasis from bronchial carcinoma
metastasis Metastasis brain metastasis from bronchial carcinoma How many genetic changes are needed for neoplastic transformation?... if you have some of these changes, but not all, you will never become
More informationCoxib s have taught us a lesson to explore more diligently the molecular and cellular pathways of inflammation
Coxib s have taught us a lesson to explore more diligently the molecular and cellular pathways of inflammation Steffen Gay Arthritis linked to cardiovascular disease CV Death Osteoarthritis CHF Rheumatoid
More informationCancer: DNA Synthesis, Mitosis, and Meiosis
Chapter 5 Cancer: DNA Synthesis, Mitosis, and Meiosis Copyright 2007 Pearson Copyright Prentice Hall, 2007 Inc. Pearson Prentice Hall, Inc. 1 What Is Cancer? Benign tumors do not invade surrounding tissue
More informationRole Of Mitochondria In Mesenchymal Stem Cells
Role Of Mitochondria In Mesenchymal Stem Cells Roman Eliseev, MD, PhD, Tamara Raymond, Regis O'Keefe, MD, PhD. University of Rochester, Rochester, NY, USA. Disclosures: R. Eliseev: None. T. Raymond: None.
More informationSpecial report. Chronic Lymphocytic Leukemia (CLL) Genomic Biology 3020 April 20, 2006
Special report Chronic Lymphocytic Leukemia (CLL) Genomic Biology 3020 April 20, 2006 Gene And Protein The gene that causes the mutation is CCND1 and the protein NP_444284 The mutation deals with the cell
More informationMomentum in Multiple Myeloma Treatment
WHITE PAPER Momentum in Multiple Myeloma Treatment Dr. Harish P. Dave, MD, MBA Dr. Ben Manderman, MD Quintiles examines promising new approaches to more effective multiple myeloma treatments. HIGH RESPONSE
More informationBone Disease in Myeloma
Bone Disease in Myeloma Boston, Massachusetts Saturday, July 26, 2008 Brian G.M. Durie, M.D. Bone Disease in Myeloma Lytic Lesions Spike Bone Marrow Plasma Cells Collapse of Vertebrae Biology of Myeloma
More informationBiotechnology. Srivatsan Kidambi, Ph.D.
Stem Stem Cell Cell Engineering-What, Biology and it Application Why, How?? to Biotechnology Srivatsan Kidambi, Ph.D. Assistant Professor Department of Chemical & Biomolecular Engineering University of
More informationIn vivo dose response assays
In vivo dose response assays Tumor assays 1. Tumor growth measurements; tumor growth delay. After irradiation, the tumor is measured daily to determine the mean diameter, or volume. Plot tumor size versus
More informationTEMA 10. REACCIONES INMUNITARIAS MEDIADAS POR CÉLULAS.
TEMA 10. REACCIONES INMUNITARIAS MEDIADAS POR CÉLULAS. The nomenclature of cytokines partly reflects their first-described function and also the order of their discovery. There is no single unified nomenclature,
More informationStem cells for brain cures
13-14/11/2006, Istituto Superiore di Sanità Rome, Italy Frontiers in Imaging Science: High Performance Nuclear Medicine Imagers for Vascular Disease Imaging (Brain and Heart) Stem cells for brain cures
More informationchronic leukemia lymphoma myeloma differentiated 14 September 1999 Pre- Transformed Ig Surface Surface Secreted Myeloma Major malignant counterpart
Disease Usual phenotype acute leukemia precursor chronic leukemia lymphoma myeloma differentiated Pre- B-cell B-cell Transformed B-cell Plasma cell Ig Surface Surface Secreted Major malignant counterpart
More informationBIOMEDICAL SCIENCES GRADUATE PROGRAM FALL 2012
THE OHIO STATE UNIVERSITY BIOMEDICAL SCIENCES GRADUATE PROGRAM FALL 2012 Reeva Aggarwal PhD Candidate MECHANISMS OF HUMAN CD34+ STEM CELL-MEDIATED REGULATION OF OSTEOPOROSIS IN A PRECLINICAL MODEL November
More informationTEXT PICTURE. Martin Puhr PhD. Medical University of Innsbruck. Department of Urology Division of Experimental Urology
TEXT PIAS1 is a determinant of poor survival and acts as a positive feedback regulator of AR signaling through enhanced AR stabilization in prostate cancer PICTURE Martin Puhr PhD Department of Urology
More informationPART 3.3: MicroRNA and Cancer
BIBM 2010 Tutorial: Epigenomics and Cancer PART 3.3: MicroRNA and Cancer Dec 18, 2010 Sun Kim at Indiana University Outline of Part 3.3 Background on microrna Role of microrna in cancer MicroRNA pathway
More informationSINPE trial, Ann Surg 2009. Overall morbidity. Minor Major. Infectious Non infectious. Post-hoc analysis WL < %5 (n=379) WL between 5-10% (n=49)
Chinese International Symposium on Nutritional Oncology Changchun, June 20-21 2014 IMMUNONUTRITION IN CANCER PATIENTS IMMUNONUTRITION IN SURGERY OBJECTIVE To get the patient undergoing major surgery for
More informationStem Cell Research: Adult or Somatic Stem Cells
Chiang 1 Stem Cell Research: Adult or Somatic Stem Cells Abstract Kelly Chiang Cluster 7 Dr. LeFebvre 07/26/10 Over the past few decades, stem cells have been a controversial topic in the scientific field.
More informationCytotoxic and Biotherapies Credentialing Programme Module 2
Cytotoxic and Biotherapies Credentialing Programme Module 2 1. The Cell Cycle 2. Cancer Therapies 3. Adjunctive Therapies On completion of this module the RN will State the difference between a normal
More informationThings You Don t Want to Miss in Multiple Myeloma
Things You Don t Want to Miss in Multiple Myeloma Sreenivasa Chandana, MD, PhD Attending Hematologist and Medical Oncologist West Michigan Cancer Center Assistant Professor, Western Michigan University
More informationClinical Cancer Research: Alternative IRB Models and Enhancing Progress
Clinical Cancer Research: Alternative IRB Models and Enhancing Progress Lowell E. Schnipper, M.D. Berenson Professor of Medicine Chief, Hematology-Oncology Beth Israel Deaconess Medical Dynamics of Clinical
More informationInternational Symposium on Malignant Mesothelioma 2011 -- curemeso.org
Measles virotherapy for malignant mesothelioma Manish R. Patel, D.O. Assistant Professor of Medicine University of Minnesota June 25, 2011 Medical Treatment of Mesothelioma Majority of patients are not
More informationA Genetic Analysis of Rheumatoid Arthritis
A Genetic Analysis of Rheumatoid Arthritis Introduction to Rheumatoid Arthritis: Classification and Diagnosis Rheumatoid arthritis is a chronic inflammatory disorder that affects mainly synovial joints.
More informationOutline of thesis and future perspectives.
Outline of thesis and future perspectives. This thesis is divided into two different sections. The B- section involves reviews and studies on B- cell non- Hodgkin lymphoma [NHL] and radioimmunotherapy
More informationMaking the switch to a safer CAR-T cell therapy
Making the switch to a safer CAR-T cell therapy HaemaLogiX 2015 Technical Journal Club May 24 th 2016 Christina Müller - chimeric antigen receptor = CAR - CAR T cells are generated by lentiviral transduction
More informationDevelopment of Bone Metastases in Men With Prostate Cancer
Development of Bone Metastases in Men With Prostate Cancer Explore the Causes Understand the Consequences Natural History of Prostate Cancer Progression Many prostate tumors may become castrate-resistant
More informationPlatelet Review July 2012. Thomas S. Kickler M.D. Johns Hopkins University School of Medicine
Platelet Review July 2012 Thomas S. Kickler M.D. Johns Hopkins University School of Medicine Hemostasis Hemostasis is the process that leads to the stopping of bleeding Hemostasis involves blood vessels,
More informationWhat is New in Oncology. Michael J Messino, MD Cancer Care of WNC An affiliate of Mission hospitals
What is New in Oncology Michael J Messino, MD Cancer Care of WNC An affiliate of Mission hospitals Personalized Medicine Personalized Genomics Genomic Medicine Precision Medicine Definition Application
More informationEnhancing Anti-Tumor Activity of Checkpoint Inhibition
Enhancing Anti-Tumor Activity of Checkpoint Inhibition Jeffrey Schlom, Ph.D. Laboratory of Tumor Immunology and Biology (LTIB) Center for Cancer Research National Cancer Institute, NIH Laboratory of Tumor
More informationNotch 1 -dependent regulation of cell fate in colorectal cancer
Notch 1 -dependent regulation of cell fate in colorectal cancer Referees: PD Dr. Tobias Dick Prof. Dr. Wilfried Roth http://d-nb.info/1057851272 CONTENTS Summary 1 Zusammenfassung 2 1 INTRODUCTION 3 1.1
More informationIdentification of CD4+ T cell epitopes specific for the breast cancer associated antigen NY-BR-1
9/8/2015 Identification of CD4+ T cell epitopes specific for the breast cancer associated antigen NY-BR-1 Stefan Eichmüller, PhD GMP & T Cell Therapy Unit, German Cancer Research Center, Heidelberg, Germany
More informationOn the origin of giant multinuclear Reed-Sternberg cells and the role of CD4 T cells in Hodgkin lymphoma
On the origin of giant multinuclear Reed-Sternberg cells and the role of CD4 T cells in Hodgkin lymphoma Uber die Entstehung von multinuklearen Reed-Sternberg Riesenzellen und die Rolle von CD4 T-Zellen
More information